Regulation - Research, Anti-Arthritics/Rheumatics

Filter

Popular Filters

Phase III data support biosimilarity of BOW-015 to Remicade

29-08-2013

Privately-held US biotech firm EPIRUS Biopharmaceuticals, which is focused on the development and production…

Anti-Arthritics/RheumaticsBiotechnologyEPIRUS BiopharmaceuticalsGenericsinfliximabRegulationRemicadeResearch

Arthritis drug disappointment: will fostamatinib's failure force pharma back to the drawing board?

10-06-2013

Recent news of fostamatinib's latest failure to meet clinical endpoints marks yet another blow to an…

Anti-Arthritics/RheumaticsAstraZenecaBiotechnologyEli LillyfostamatinibPfizerPharmaceuticalRegulationResearchRigel PharmaceuticalstabalumabXeljanz

News briefs: Pfizer's filiburvir; Sanofi's Plavix; EMA sued over transparency

11-03-2013

Among a batch of news reported over the weekend, US drugs behemoth Pfizer (NYSE: PFE) has halted development…

AbbVieAnti-Arthritics/RheumaticsAnti-viralsBiotechnologyCardio-vascularEuropefiliburvirHumiraInterMuneNorth AmericaPfizerPharmaceuticalPlavixRegulationResearchSanofi

Positive new data for Pfizer's tofacitinib; possible regulatory delay

01-08-2012

Pfizer (NYSE:PFE), the world's largest drugmaker by sales, yesterday released positive top-line results…

Anti-Arthritics/RheumaticsNorth AmericaPfizerPharmaceuticalRegulationResearchtofacitinib

Merck & Co closes odanacatib trial early on good results in osteoporosis

13-07-2012

US drug giant Merck & Co (NYSE: MRK) says it is halting a Phase III trial of its investigational osteoporosis…

Anti-Arthritics/RheumaticsMerck & CoodanacatibPharmaceuticalRegulationResearch

COMPANY SPOTLIGHT

Menarini

Back to top